2025-11-23 - Analysis Report
Okay, here's the report analyzing Eli Lilly (LLY) based on the provided data.

**Report: Eli Lilly & Co. (LLY) Analysis**

Eli Lilly and Co. is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO)**

*   **Cumulative Return (LLY):** 303.45%
*   **Cumulative Return (VOO):** 94.64%
*   **Absolute Spread:** 192.8
*   **Relative Spread:** 80.2

**Analysis:** LLY has significantly outperformed the S&P 500. The relative spread of 80.2 indicates that LLY's outperformance is positioned high within its historical range of deviation from the S&P 500.

**Alpha, Beta Analysis**

| Year       |   CAGR |   MDD |   Alpha |   Beta |   Cap(B) |
|:-----------|-------:|------:|--------:|-------:|---------:|
| 2015-2017  |   11   |  76.1 |   -17   |   -0   |     75.7 |
| 2016-2018  |   39   |  68.9 |    24   |    0.1 |    103.7 |
| 2017-2019  |   41   |  68.9 |    19   |    0.4 |    117.8 |
| 2018-2020  |   34   |  79.8 |    10   |    0.3 |    151.4 |
| 2019-2021  |   53   |  79.8 |     7   |    0.5 |    247.6 |
| 2020-2022  |   64   |  79.8 |    65   |    0.4 |    328   |
| 2021-2023  |  125   |  78.9 |   124   |    0.2 |    522.6 |
| 2022-2024  |  134   |  81.2 |   113   |    0.2 |    692.1 |
| 2023-2025  |  195   |  83.5 |   136   |    0.2 |    950   |

**Analysis:**

*   **CAGR:**  Compounded Annual Growth Rate has been dramatically increasing over the observed periods, indicating accelerating growth.
*   **MDD:** Maximum Drawdown is high, implying significant volatility and potential risk.
*   **Alpha:**  Consistently positive Alpha values (especially in recent years) suggest LLY's performance is driven by factors other than the market itself (stock-picking ability or unique factors).
*   **Beta:**  Low Beta values indicate LLY is less sensitive to market movements than the S&P 500.
*   **Cap(B):**  Market capitalization has shown massive growth, reflecting the company's increasing value.

**2. Recent Stock Price Movement**

*   **Current Price:** 1059.70
*   **Previous Close:** 1043.29 (Change: 1.57%)
*   **5-Day Moving Average:** 1040.87
*   **20-Day Moving Average:** 951.41
*   **60-Day Moving Average:** 837.55

**Analysis:** The price is above all moving averages, indicating a strong uptrend.  The recent price increase of 1.57% from the previous close suggests continued positive momentum.

**3. Technical Indicators & Outlook**

*   **Market Risk Indicator (MRI):** 0.8 (Medium Investment Recommendation)
*   **RSI:** 81.99 (Overbought)
*   **PPO:** 0.53
*   **Hybrid Signal:** Buy 100% of cash
*   **Delta Previous Relative Divergence:** 13.5 (+) (Short-term Increase)
*   **Expected Return:** 53.9% (Long-term outperformance vs. S&P 500)

**Analysis:**

*   The MRI suggests a medium level of investment risk.
*   The RSI is in overbought territory, indicating a potential pullback in the short term.
*   The positive PPO suggests positive momentum.
*   The Hybrid Signal recommends a buy.
*   The increase in relative divergence indicates that LLY's recent gains relative to the S&P 500 are accelerating.
*   The 53.9% expected return suggests significant long-term potential. The positive change since the previous close could indicate some price volatility due to recent news.

**4. Recent News & Significant Events**

*   LLY became the first pharma group to join the $1 trillion club.
*   LLY's market cap reached $1 trillion after climbing $400 billion in 3 months.
*   LLY is in focus alongside Nvidia and Apple.

**Analysis:** Recent news is overwhelmingly positive, driven by the company's achievement of a $1 trillion market capitalization. This milestone is driving investor sentiment and supporting the stock's upward momentum.

**4-2. Analyst Opinions**

*   **Consensus:** Buy
*   **Mean:** 1.77 (~Buy)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 1012.19 / 1500.00 / 770.00

**Analysis:** Analyst sentiment is generally positive, with a consensus rating of "Buy." The average target price is slightly below the current price, but there is a wide range in target prices, with some analysts being highly optimistic.

**5. Recent Earnings Analysis**

| Date       |    EPS | Revenue     |
|:-----------|-------:|:------------|
| 2025-10-30 |   6.22 | 17.60 B$    |
| 2025-08-07 |   6.3  | 15.56 B$    |
| 2025-05-01 |   3.07 | 12.73 B$    |
| 2024-10-30 |   1.08 | 11.44 B$    |
| 2025-10-30 |   1.08 | 11.44 B$    |

**Analysis:** Recent earnings data shows strong growth in both EPS and revenue, indicating solid financial performance.

**6. Financial Information**

| Quarter    | Revenue   | Profit Margin   |
|:-----------|:----------|:----------------|
| 2025-09-30 | $17.60B   | 82.91%          |
| 2025-06-30 | $15.56B   | 84.27%          |
| 2025-03-31 | $12.73B   | 82.53%          |
| 2024-12-31 | $13.53B   | 82.24%          |
| 2024-09-30 | $11.44B   | 81.02%          |

| Quarter    | Equity    |     ROE |
|:-----------|:----------|--------:|
| 2025-09-30 | $23.79B   |  23.46  |
| 2025-06-30 | $18.27B   |  30.98  |
| 2025-03-31 | $15.76B   |  17.5   |
| 2024-12-31 | $14.19B   |  31.07  |
| 2024-09-30 | $14.24B   |   6.81  |

**Analysis:**

*   **Revenue and Profitability:** Revenue is increasing consistently, and profit margins are exceptionally high and stable.
*   **Capital and Profitability:** Equity is growing, and ROE (Return on Equity) is strong, indicating efficient capital utilization.

**7. Overall Summary**

Eli Lilly (LLY) is exhibiting strong financial performance and positive market sentiment.  Key takeaways:

*   **Outperformance:** LLY has significantly outperformed the S&P 500.
*   **Growth:**  Rapid revenue and earnings growth.
*   **Profitability:** Very high and stable profit margins.
*   **Momentum:** Strong uptrend in stock price.
*   **Positive News:** Achieving a $1 trillion market cap is boosting investor confidence.
*   **Analyst Sentiment:** Generally positive.
*   **Risks:** The RSI indicates the stock may be overbought in the short term and could face a pullback. High MDD is a risk.
*   **Investment Recommendation:** The MRI suggests a medium level of investment risk. The Hybrid Signal recommends a buy.

**In conclusion:**  LLY presents a compelling investment opportunity due to its strong growth, high profitability, and positive market momentum. However, investors should be aware of the potential for a short-term pullback due to overbought conditions and the general volatility implied by the MDD and should consider a long-term investment horizon.
